The estimated Net Worth of Bioscience Plc Arix Bioscie... is at least $73.1 Million dollars as of 16 July 2020. Bioscience Bioscie owns over 597,587 units of Harpoon Therapeutics stock worth over $54,796,842 and over the last 6 years Bioscience sold HARP stock worth over $18,341,964.
Bioscience has made over 7 trades of the Harpoon Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently Bioscience sold 597,587 units of HARP stock worth $4,601,420 on 16 July 2020.
The largest trade Bioscience's ever made was buying 700,000 units of Harpoon Therapeutics stock on 23 October 2018 worth over $7,000,000. On average, Bioscience trades about 373,153 units every 90 days since 2018. As of 16 July 2020 Bioscience still owns at least 2,381,436 units of Harpoon Therapeutics stock.
You can see the complete history of Bioscience Bioscie stock trades at the bottom of the page.
Bioscience's mailing address filed with the SEC is 1 Berkeley St, Mayfair, London W1J 8DJ, UK.
Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt, and Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics executives and other stock owners filed with the SEC include: